Eli Lilly said post-hoc analyses of its Phase 3 ATTAIN-1 trial found that Foundayo, orforglipron, was associated with lower modeled 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or overweight and a weight-related condition. The findings were published in Diabetes, Obesity and Metabolism.
At 72 weeks, participants taking the highest 17.2-milligram dose had a modeled 57% reduction in predicted type 2 diabetes risk compared with placebo. Predicted cardiovascular disease risk was 18% lower than placebo in the same dose group. The analyses used the Cardiometabolic Disease Staging risk engine for diabetes and a body mass index-based Framingham model for cardiovascular disease.
The lower 5.5-milligram and 9-milligram doses were associated with estimated reductions in predicted diabetes risk of 45% and 50%, respectively. Those doses were associated with estimated reductions in modeled cardiovascular risk of 13% and 15%.
ATTAIN-1 enrolled 3,127 adults without diabetes who had obesity, or overweight plus at least one weight-related condition. The randomized, double-blind, placebo-controlled Phase 3 trial compared three once-daily oral doses of Foundayo with placebo over 72 weeks. Its primary objective was weight reduction, not the prediction models reported in the new analysis.
Foundayo is a once-daily, non-peptide GLP-1 receptor agonist. Lilly said the product is approved for chronic weight management in adults with obesity, or certain adults with overweight and a weight-related medical condition, alongside diet and physical activity.
The reported results are model-based estimates of future risk, rather than observed reductions in new diabetes diagnoses or cardiovascular events during the 72-week study.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!